HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the Company's groundbreaking 12-lead electrocardiogram (ECG) synthesis software designed for the assessment of rhythms and arrhythmias, including sinus rhythm, atrial fibrillation, atrial flutter, bradycardia, tachycardia, and sinus with premature ventricular contraction (PVC) or premature atrial contraction (PAC).
The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five clinical sites. The Company believes the study's findings support the clinical equivalence of HeartBeam's synthesized 12-lead ECG where the leads are similar to standard 12-lead ECGs for rhythm and arrhythmia assessment.
The submission builds on HeartBeam's recent FDA clearance for its patented technology which captures the heart's electrical signals from three distinct directions. The software synthesizes these signals into a familiar 12-lead ECG using a personalized transformation matrix.
Upon FDA clearance for the software, the Company plans to initiate commercial launch leveraging the learnings and feedback gained from its Early Access Program. Hundreds of physicians and patients have already joined the waitlist underscoring the widespread interest in a powerful and convenient cardiac monitoring option that can be used outside of a medical facility.
Robert Eno, Chief Executive Officer of HeartBeam, commented, 'The FDA submission for the 12-lead synthesis software is a significant step as we work towards fulfilling HeartBeam's vision to offer patients and physicians an easy-to-use portable device and transform how cardiac conditions are monitored and detected.'
Additional future planned advances include the integration of AI-based classification algorithms and detection of heart attacks to aid in reducing 'symptom to door' times – an area of major focus for the American Heart Association (AHA) to shorten the time from heart attack symptom onset and treatment. HeartBeam believes its groundbreaking technology presents a transformative opportunity to bring about a paradigm shift in cardiovascular care for millions of patients globally.
Additional Details About Data Supporting FDA Submission
The FDA submission was supported by data from the VALID-ECG pivotal study, which completed enrollment in June 2024. VALID-ECG used the same protocol as an 80-person pilot study which was presented at the AHA 2024 Scientific Sessions. The Company plans to present the results from VALID-ECG at a scientific conference in 2025.
Data from the pilot study presented at the AHA Scientific Sessions, which also supported the FDA submission, found similar performance of HeartBeam's synthesized 12-lead ECG waveforms compared to simultaneously collected standard 12-lead ECGs for arrhythmia detection. The pilot study found excellent agreement when physicians diagnosed various arrhythmias utilizing the HeartBeam synthesized 12-lead ECG compared to a standard 12-lead ECG (Sensitivity: 94%, Specificity: 100%). Arrhythmias evaluated include sinus rhythm, atrial fibrillation, atrial flutter, and sinus with premature ventricular contraction (PVC) or premature atrial contraction (PAC).
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free synthesized 12-lead ECG capable of capturing the heart's electrical signals from three distinct directions. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement. For additional information, visit HeartBeam.com.
About the HeartBeam System
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual.
Forward-Looking Statements
All statements in this release that are not based on historical fact are 'forward-looking statements.' While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
SOURCE: HeartBeam, Inc.
Copyright Business Wire 2025.
PUB: 01/29/2025 08:31 AM/DISC: 01/29/2025 08:31 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
28 minutes ago
- USA Today
FDA warns of radioactive contamination in some frozen shrimp sold at Walmart
The Food and Drug Administration is recalling frozen shrimp sold at Walmart for possible radioactive chemical contamination. The FDA advised the recall in an Aug. 19 notice, saying certain raw frozen shrimp products processed by Indonesian company PT. Bahari Makmur Sejati (doing business as BMS Foods) had tested positive for Cesium-137, or Cs-137. Walmart sells the products under its Great Value brand. The presence of the chemical element violates the Federal Food, Drug, and Cosmetic Act, said the FDA, as it appears the affected product may have been "prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern." Here's what to know. Which products are recalled? Two-pound bags of Great Value brand Frozen Raw Ez Peel Tail-On Farm-Raised White Vannamei Shrimp are subject to the recall. Lot codes and best by dates include the following: What is Cesium-137 (Cs-137) and why is it regulated? Cs-137 is a radioisotope of cesium, meaning it is a chemical element that emits radiation as it breaks down. It is man-made and is produced by nuclear fission, according to the FDA. In the United States, it is used in medical devices and measurement gauges, such as industrial devices that measure the thickness of materials. Because it is widespread around the globe, trace amounts can be found in the environment, including soil, food and air, said the FDA. Agencies, including the FDA and U.S. Customs & Border Protection, test for, monitor and regulate the presence of the substance due to the risks associated with long-term exposure. The FDA said low-level radiation exposure over time can lead to serious health complications. Exposure to Cs-137 alone can cause burns, acute radiation sickness, cancer and death. As a result, the governing agencies restrict potential exposure to lessen the possibility of these long-term impacts. The FDA said the presence of Cs-137 was confirmed in one sample of breaded shrimp, which was denied entry into the United States. "FDA has concluded that the level detected in the breaded shrimp sample could represent a potential health concern for those exposed to this level of Cs-137 from consumption of the shrimp over an extended period of time combined with radiation that exists in the environment and from other sources such as medical procedures," the agency said in a statement. While Cs-137 was only detected in a single shipment thus far, that does not mean other products made by the same manufacturer are not impacted. PT. Bahari Makmur Sejati has also been placed on an import alert that prevents any of their food products from entering the United States until it resolves any conditions that could have caused the exposure. Where were the recalled shrimp sold? According to Walmart, shrimp products made by PT. Bahari Makmur Sejati were distributed in 13 states. What to do if you have recalled shrimp If you have a package of the recalled Walmart shrimp at home, throw it away and do not eat or serve it, said the FDA. Distributors and retailers should dispose of the product and should not sell or serve it. Those who fear they may have been exposed to elevated levels of cesium should contact their medical provider. To make a complaint or report an adverse reaction, consumers can visit the FDA's Industry and Consumer Assistance portal.
Business Wire
28 minutes ago
- Business Wire
KBRA Assigns a AAA Rating to County of Henrico, VA GO Public Improvement Bonds, Series 2025A and Assigns AA+ Rating to the Economic Dev. Authority of Henrico County, VA Revenue Bonds, Series 2025B; Stable Outlook
NEW YORK--(BUSINESS WIRE)--KBRA assigns a AAA rating to the County of Henrico, VA General Obligation Public Improvement Bonds and assigns a AAA rating to outstanding General Obligation bonds. KBRA also assigns a AA+ rating to the Economic Development Authority of Henrico County, VA Revenue Bonds, Series 2025B and assigns a AA+ rating to outstanding appropriation debt. All ratings with a Stable Outlook. To access ratings and relevant documents, click here. Click here to view the report. Methodologies Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1010909
Business Wire
28 minutes ago
- Business Wire
VTEX Turns Enterprise Complexity into Competitive Edge with Scalable B2B Orchestration, Agentic AI, and Omnichannel Intelligence
NEW YORK--(BUSINESS WIRE)-- VTEX (NYSE: VTEX), the backbone for connected commerce and the only vendor named a Gartner® ' Customers' Choice ' for two consecutive years, unveiled a bold expansion of its enterprise-grade capabilities at VTEX Vision 2025, its annual digital showcase. This year's release introduces new solutions tailored for B2B complexity, personalized omnichannel experiences, and an agentic AI workforce that drives operational excellence through automation. B2B Enterprise: Tailored Capabilities That Convert and Scale The report by Andy Hoar recognized VTEX with the most Gold medals across Enterprise and Mid-Market categories, including Total Cost of Ownership (TCO) and Marketplace capabilities. B2B commerce runs on its own terms, demanding intuitive digital infrastructure that's built to move high-volume transactions and manage the full complexity of modern procurement. VTEX Vision for B2B has unveiled core capabilities: Personalized Catalogs, Pricing, and Payment Methods per Buyer. Advanced Buyer Organization Management with branch structures, role-based access, budgeting, and policy control. Buying Policies & Approval Workflows that enforce custom procurement rules automatically. Quick Order Tools by file and search term for rapid cart creation. SKU Matrix and Reorder Tools for high-frequency purchasing. Native Punchout Integrations to centralize procurement within enterprise systems. VTEX's continued stream of B2B innovation affirms what enterprise leaders already know: success requires infrastructure built around how corporate buyers manage procurement, not systems that restrict transactions. Omnichannel, Evolved: Seamless, Intelligent and Personal For enterprise brands, true omnichannel is still a moving target. Inventory silos, delayed delivery updates, and disconnected store operations continue to prevent many from operating at full potential. VTEX closes these gaps by strengthening the operational backbone needed by brands to move with speed, accuracy, and full control of fulfillment. Key capabilities include: AI Semantic Search delivers relevant results by interpreting shopper intent through natural language. AI Product Recommendations drive conversion with personalized, behavior-based suggestions. Distributed Inventory is unified and available across every channel: B2C, B2B, marketplaces, and stores. Multi-Seller Carts merge 1P, 3P, and in-store items into one seamless checkout experience. Delivery Promise helps shoppers find products that are located near them and that can be delivered quickly. Cross-Channel Fulfillment: Newly simplified BOPIS (buy online, pick up in store) and Ship from Store features, simplified returns, leading to operational cost reductions and improved inventory accuracy. Agentic Commerce: The Enterprise AI Workforce Enterprise commerce is entering a new operational era. VTEX is leading that shift with agentic AI built to streamline critical workflows and accelerate enterprise performance worldwide. The first phase of its roadmap toward a fully agentic commerce platform launches three AI agent specialists engineered for precision, speed, and adaptability. Together, they signal the beginning of a new standard where digital infrastructure operates as intelligently as the enterprises it serves. Customer Service Agent: a fully autonomous support agent across WhatsApp, Instagram, SMS, and more. Deployed by brands like UNICEF and Cencosud, it has already resolved 92% of tickets without human input and cut AHT from hours to minutes. Visual Editor Agent: will soon allow any team to instantly update a storefront using a Figma file or natural language, no developers required. Data Insights Agent: receive priority access to real-time omnichannel performance data in plain language, without the need for static dashboards or SQL queries. ' Enterprise commerce doesn't slow down in the face of complexity. It rewards those who turn it into leverage. With VTEX Vision 2025, we have expanded our infrastructure to meet rising demands, from B2B buyer personalization to seamless consumer retail experiences, all on one unified commerce platform built for growth, ' said Mariano Gomide de Faria, Founder and Co-CEO of VTEX. ' As VTEX advances toward a fully agentic commerce platform, we continue to transform cost centers into engines of growth with measurable impact. Our first wave of AI agents marks a critical step, compressing complex workflows and unlocking new value for global brands. Flexibility, transparency, and real-time adaptability will define the next generation of enterprise leaders. Anything else will be left behind. ' One Platform. Infinite Control. VTEX is building the commerce infrastructure enterprises need to unlock growth across both B2C and B2B models. Whether it's enabling a buyer to place highly complex orders with hundreds of line items or approval hierarchies in seconds, orchestrating global fulfillment across 20 countries, or deploying an AI agent that turns data into action, VTEX gives enterprise brands one platform to manage it all. Explore VTEX Vision 2025 and see what the future of enterprise commerce looks like for your business. ABOUT US: VTEX (NYSE: VTEX) is the backbone of AI-connected commerce, built for enterprises that move fast, adapt with precision, and expect results. Trusted by retail (B2C) and industrial (B2B) leaders, VTEX unifies omnichannel sales, intelligent order management, data pipelines, retail media, enterprise-grade security, and more. Each capability is designed to remove friction, connect operations, and accelerate growth. VTEX provides both composable and out-of-the-box solutions and is trusted by more than 2,400 brands including Colgate, Sony, Stanley Black & Decker, and Whirlpool. Today, VTEX powers over 3,400 active storefronts in 43 countries (fiscal year ended December 31, 2024). Learn more at
